Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Clinical trial NCT05263947 · COMPLETED

Trial details

NCT number: NCT05263947
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Bevacizumab Tyrosine Kinase Inhibitor EGFR L858R

Start date: 2022-01-30
Primary completion: 2023-12-30
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.